Mirodenafil

米罗那非

Report date: 2026/03/30 17:02:26

Base Information

Drug NameMirodenafil
Drug Alias NameMirodenafil hydrochloridepyrrolo[3,2-delta]pyrimidin-4-one derivativesiMvixxBravontoM-vix +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodiesterase 5A inhibitors
TargetsPhosphodiesterase 5A
Therapy Area/IndicationsRenal InsufficiencyKidney DiseasesUrologic Diseases +[5] 
Global Approved IndicationsErectile Dysfunction
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2007/08/01
Country/TerritorySouth KoreaMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSk Chemicals
China Registration ClassN/A

Develop Information

Active CompaniesPanacro (Hefei) Pharmaceutical Technology Co LtdSk ChemicalsAribio Co Ltd
Inactive CompaniesSk Chemicals Co Ltd
Active IndicationsErectile DysfunctionAlzheimer Disease
Inactive IndicationsRenal InsufficiencyKidney DiseasesUrologic Diseases

Other Information

ATC CodeG04BE
Related LinksWikipediaDrugBank